Clinical trials: Metformin
Diabetes, Pregnancy
Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)
Purpose: The objective of this proposal is to study the safety and efficacy of metformin added to insulin for treatment of type 2 diabetes mellitus (T2DM) among pregnant women.
- Trial name
- MOMPOD (NCT02932475)
- Testing
- Metformin
- Where
- 10 sites in United States
- Volunteers
- 831 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea)…
- Trial name
- NCT02471404
- Testing
- Dapagliflozin, Saxagliptin, Glimepiride
- Where
- 173 sites in Czechia, Germany and 3 more
- Volunteers
- 939 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe, North and South America. The aim of the trial is to compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral…
- Trial name
- SUSTAIN 8 (NCT03136484)
- Testing
- Semaglutide, Canagliflozin
- Where
- 119 sites in United States, Argentina and 10 more
- Volunteers
- 788 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients
Secondary failure of sulfonylureas (SUs) can occur in about 30%-40% of type 2 diabetic patients after treatment with SUs for 5 years, although SUs are widely used in type 2 diabetic patients.
- Trial name
- NCT02099838
- Testing
- Pioglitazone and Metformin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Huazhong University of Science and Technology
Type 2 Diabetes Mellitus
Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin
Primary Objective: To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area…
- Trial name
- NCT01596504
- Testing
- Lixisenatide (AVE0010), Liraglutide, Insulin Glargine
- Where
- 8 sites in Germany
- Volunteers
- 142 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome
The investigators are examining the activation of insulin signaling factors in skeletal muscles of human diabetics. The investigators are characterizing the defects in signaling, and are examining the effects of anti-diabetic…
- Trial name
- NCT00690755
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin…
- Trial name
- NCT01477853
- Testing
- Sitagliptin, Atorvastatin, Metformin (open-label)
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes, Diabetes Mellitus, Type 2
Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Asia, South America and the United States of America (USA). The aim of this clinical trial is to determine whether two insulin treatments given once daily are equally effective with respect to the blood…
- Trial name
- EFFICACY (NCT00909480)
- Testing
- insulin detemir, insulin glargine
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 457 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin
The purpose of this study is to compare the effects of saxagliptin with those of placebo as add-on therapy to insulin and insulin with metformin in improving glycemic control at 24 and 52 weeks.
- Trial name
- NCT00757588
- Testing
- Saxagliptin, 5 mg + insulin
- Where
- 80 sites in United States, Canada and 8 more
- Volunteers
- 455 people
- Sponsor
- AstraZeneca
Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
This phase III trial studies how well metformin hydrochloride works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT01905046
- Testing
- metformin hydrochloride
- Where
- 27 sites in United States
- Volunteers
- 86 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Diabetes Mellitus
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with…
- Trial name
- NCT00755846
- Testing
- Alogliptin
- Volunteers
- 265 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician.
- Trial name
- NCT02111096
- Testing
- LY2409021, Sitagliptin, Metformin
- Where
- 33 sites in United States, Greece and 2 more
- Volunteers
- 174 people
- Sponsor
- Eli Lilly and Company
Pregnancy Complications
Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes
Pregnant women with type 2 diabetes mellitus (T2DM) are at increased risk for miscarriages, birth defects, large infants, and stillbirths. Maintaining blood sugars in the normal range decreases these pregnancy complications.
- Trial name
- NCT00678080
- Testing
- Metformin, Insulin (NPH and Regular)
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Pulmonary Artery Hypertension
Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension
The primary objective of this study is to determine the impact of two interventions against insulin resistance on the composite endpoint of 10% improvement in baseline six minute walk distance or improvement in World Health…
- Trial name
- NCT03617458
- Testing
- Metformin, mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-402)
This is a multicenter, observational, retrospective and cross-sectional study to be conducted in a cohort of consecutively selected participants with type 2 diabetes mellitus (T2DM) who have been treated with sulphonylurea (SU)…
- Trial name
- NEEDS (NCT01278485)
- Testing
- Sulphonylurea, Metformn
- Volunteers
- 726 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity, Type 2 Diabetes Mellitus
Metformin in Overweight Type 2 Diabetes Mellitus
The study included 102 overweight type 2 diabetes mellitus patients with a body mass index (BMI) of more than 25 in an open label study.
- Trial name
- NCT00922194
- Testing
- Extended Release Metformin
- Where
- India
- Volunteers
- 102 people
- Sponsor
- Era's Lucknow Medical College
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe).
- Trial name
- onset 9 (NCT03268005)
- Testing
- Faster-acting insulin aspart, Insulin aspart, Insulin degludec
- Where
- 167 sites in United States, Argentina and 16 more
- Volunteers
- 1,264 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin
This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin
- Trial name
- NCT01517373
- Testing
- PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 304 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine and lifestyle approaches will be…
- Trial name
- NCT02561130
- Testing
- insulin glargine, metformin, Forxiga
- Where
- 7 sites in Canada
- Volunteers
- 154 people
- Sponsor
- Population Health Research Institute